Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Pretax income is the income that a company earns before paying income taxes. Universe Pharmaceuticals's pretax income for the
six
months ended in Mar. 2026 was $-1.56 Mil.
Its pretax income for the trailing twelve months (TTM) ended in Mar. 2026 was $-1.94 Mil.
Universe Pharmaceuticals's pretax margin was -17.21%.
During the past 8 years, Universe Pharmaceuticals's highest Pretax Margin was 33.38%. The lowest was -35.27%. And the median was 7.56%.
During the past 8 years, Universe Pharmaceuticals's highest Pretax Margin was 33.38%. The lowest was -35.27%. And the median was 7.56%.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Universe Pharmaceuticals Pre-Tax Income Related Terms
Universe Pharmaceuticals Pre-Tax Income Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
UPC vs NPHC, CBIH, SXTC: Pre-Tax Income Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Universe Pharmaceuticals's Pre-Tax Income, along with its competitors' market caps and Pre-Tax Income data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Universe Pharmaceuticals Pre-Tax Income vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Universe Pharmaceuticals's Pre-Tax Income distribution charts can be found below:
* The bar in red indicates where Universe Pharmaceuticals's Pre-Tax Income falls into.
Pre-Tax Income for the trailing twelve months (TTM) ended in Mar. 2026 adds up the semi-annually data reported by the company within the most recent 12 months, which was $-1.94 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Universe Pharmaceuticals (UPC) has a Pre-Tax Income of $-1.94 Mil as of Mar. 2026. Pre-Tax Income is the total earnings before taxes but after all operating and interest expenses. View historical data on Universe Pharmaceuticals and its competitors.
Is Universe Pharmaceuticals' Pre-Tax Income too high?
Universe Pharmaceuticals' current Pre-Tax Income is $-1.94 Mil. Overall, Universe Pharmaceuticals has a GF Score™ of 54/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Universe Pharmaceuticals' Pre-Tax Income compare to NPHC and CBIH?
Universe Pharmaceuticals' Pre-Tax Income of $-1.94 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pre-Tax Income for a Drug Manufacturers company?
A good Pre-Tax Income depends on the Drug Manufacturers industry context. However, Pre-Tax Income should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pre-Tax Income mean?
A high Pre-Tax Income can signal that a stock is expensive relative to its fundamentals. Pre-Tax Income is the total earnings before taxes but after all operating and interest expenses. View historical data on Universe Pharmaceuticals and its competitors. Universe Pharmaceuticals's current Pre-Tax Income is $-1.94 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Universe Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Universe Pharmaceuticals (UPC) is currently considered Significantly Overvalued. The stock's GF Value™ is $2.78, compared to a current price of $5.36 — trading 92.8% above its estimated fair value. The current Pre-Tax Income is $-1.94 Mil. Universe Pharmaceuticals' overall GF Score™ is 54/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pre-Tax Income calculated?
Pre-Tax Income is calculated from a company's financial statements. For Universe Pharmaceuticals (UPC), the current Pre-Tax Income is $-1.94 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Universe Pharmaceuticals (UPC) Overvalued in 2026?
Based on GuruFocus' analysis, Universe Pharmaceuticals stock appears to be overvalued.
The current stock price of $5.36 is trading 92.8% above its estimated GF Value™ of $2.78.
GuruFocus considers Universe Pharmaceuticals to be Significantly Overvalued.
Key valuation signals for UPC:
Pre-Tax Income: $-1.94 Mil
GF Value™: $2.78 vs. price of $5.36 (92.8% above fair value)
No single metric tells the full story. See the UPC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Universe Pharmaceuticals Inc is a pharmaceutical company specializing in the manufacturing, marketing, sales and distribution of traditional Chinese medicine derivatives products targeting the elderly with the goal of addressing their physical conditions in the ageing process and promoting their general well-being. The company also sells biomedical drugs, medical instruments, Traditional Chinese Medicine Pieces, and dietary supplements manufactured by third-party pharmaceutical companies. Its products are under two categories namely treatment and relief for common chronic health conditions in the elderly designed to achieve physical wellness and longevity (Chronic Condition Treatments), and cold and flu medications.
54GF Score
Get the complete analysis for UPC
Pre-Tax Income is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
UPC has been successfully added to your 
